

# Favourable Long-Term Transplant Outcomes with Tacrolimus

Dear {{customText[Dr|Prof|A|Prof|Mr|Ms]}} {{accFName}} {{accLName}},

For the past 30 years, tacrolimus has shown success in meeting the immunosuppressive needs of kidney and liver transplant patients.<sup>\*, 1-4</sup>

Demonstrating Astellas' continuous commitment to generate updated clinical evidence, three recent studies aimed to explore the long-term renal transplant clinical outcomes with tacrolimus treatment.<sup>2-4</sup>

Long-term follow-up study	Treatment regimen	Follow-up patient set	Primary endpoint(s)	Graft survival	Patient survival
<b>ADMIRAD (Retrospective, non-interventional 10-year follow up)</b> Kuypers D, <i>et al.</i> (2023) <sup>2</sup>	Prolonged-release (PR) vs immediate-release (IR) tacrolimus	172	Composite endpoint (graft loss, BCAR and graft dysfunction)	74.1%	88.0%
<b>ADVANCE (Prospective non-interventional 5-year follow up)</b> Pernin V, <i>et al.</i> (2023) <sup>3</sup>	PR tacrolimus + basiliximab + MMF + intraoperative corticosteroid bolus (with or without tapered corticosteroids up to Day 10)	814	Overall graft survival	88.1%	94.4%
<b>JACK (Real-world retrospective 10-year follow-up)</b> Okumi M, <i>et al.</i> (2023) <sup>4</sup>	PR tacrolimus + concomitant MMF and methylprednisolone + basiliximab induction	410	Death-censored graft failure and all-cause death	93.0%	93.2%

Low graft failure rates and high patient survival rates were observed in the long-term studies.<sup>2-4</sup> Stable renal function was maintained throughout the follow-up period and no new safety signals were identified.<sup>2,3</sup>



**Please do not hesitate to reach out should you require further information. Thank you.**

\*From first solid organ transplant approval of Prograf in the United States, and represents 1st milestone for Astellas in the field of transplantation.

Please refer to your locally approved label for Prograf and Advagraf.

**References:** 1. Mourad G, *et al.* Transplantation. 2017;101:1924–1934. 2. Kuypers D, *et al.* Transplant Direct 2023;9:e1465. 3.

**Abbreviation:** ADMIRAD, Adherence Measurement in Stable Renal Transplant Patients Following Conversion From PROGRAF to ADVAGRAF; ADVANCE, ADVAGRAF-based Immunosuppression Regimen Examining New Onset Diabetes Mellitus in Kidney Transplant Recipients; BCAR, biopsy-confirmed acute reject; IR, immediate-release; JACK, Japan Academic Consortium of Kidney Transplantation; MMF, mycophenolate mofetil; PR, prolonged-release.



SCAN BELOW QR CODE  
FOR ABBREVIATED  
PRESCRIBING INFORMATION



SCAN TO SUBMIT QUESTIONS  
ABOUT PRODUCTS



Adverse events should be reported to the local regulatory authority and Astellas office. Email: [pv.my@astellas.com](mailto:pv.my@astellas.com).

For healthcare professionals only.

Astellas is committed to protecting your personal information and will only use it in accordance with the applicable data privacy law and our Astellas Privacy Notice. For further information on how we process and protect your personal information and how you may exercise your data protection rights, please refer to our Privacy Notice at <https://www.astellas.com/my/privacy-policy>.

IMPORTANT: Your consent is voluntary, and you can withdraw it any time by clicking the [unsubscribe link](#) in any email communication. However, if you withdraw your e-marketing consent, Astellas will not be able to continue certain services, like sending you medical updates and/or marketing information about Astellas products, services, news, research and activities via e-mail.



Astellas Pharma Malaysia Sdn Bhd  
Suite 18.05, Level 18, Centerpoint North Tower, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur  
Tel: +603-2202 6999 [www.astellas.com](http://www.astellas.com)

MAT-MY-PRO-2024-00002